Weitman, Steve


Steve obtained his MD and PhD at the Medical College of Wisconsin. He is a Pediatric Hematology/Oncologist with about 30 years of experience in cancer drug development. Steve was Professor (with tenure) and Director of the Institute for Drug Development as well as the AT&T Distinguished Chair for Drug Development at the University of Texas Health Science Center at San Antonio.  He was previously Chief Medical Officer, Senior Vice President, and Member of the Executive Committee at ILEX Oncology where he led ILEX’s successful development of clofarabine (Clolar™) and guided that product through a successful ODAC and FDA approval. He also worked on the FDA approval of pralatrexate and romidepsin as well as the post-approval commitments for campath. A major focus of his research has been on the transition of new compounds from laboratory to human Phase I studies.  He has also focused on developing new trial designs for Phase 1, 2a and 2b clinical trials in medicine. Steve is inventor on numerous patents and author of over 200 papers, abstracts and chapters in the medical literature. Steve is also a consultant to various biotech and pharmaceutical companies, past Associate Editor of Investigational New Drugs and reviewer for multiple journals including the American Journal of Pediatric Hematology/Oncology, Clinical Cancer Research, Cancer Research, and the Journal of Clinical Oncology.